ImetelChat

sdrawkcabeman post yesterday on the YMB:

"I was just browsing the Geron homepage and noticed under the "For Patients" tab, there's a page for "Hematologic Malignancies." In the past, when they described hematologic malignancies, it was strictly in context of myeloid, they did't mention anything else; but now they include a paragraph about lymphocytic. I thought it was interesting that they'd put information about conditions they're not (yet) pursuing. It is a natural progression of Imet to pursue the totality of blood indications, I just thought it was interesting to see that on the website. JNJ will certainly have pursued preclinicals with combos to measure Imet in lymphocytic malignancies to robustly gauge the value of a drug they're licensing.

Also, you'll see that page gives the same emphasis to AML as it does MF and MDS. It's clear AML is already mature on their agenda. The website is guiding eyes to where they should be looking. I won't be at the meeting, but I wish I could ask how viable the IDP is in contrast to any acquisitions; I suppose they couldn't answer anyway. Anyone going?"

Interesting observation. However, in the graph called 'Hematologic Malignancies' they have left out the lymphocytic types. So I see it more as a general way of explaining and positioning the myeloid malignancies which they are pursuing. AML indeed seems to be part of that.